These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 15630452)

  • 1. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART.
    Wang FX; Xu Y; Sullivan J; Souder E; Argyris EG; Acheampong EA; Fisher J; Sierra M; Thomson MM; Najera R; Frank I; Kulkosky J; Pomerantz RJ; Nunnari G
    J Clin Invest; 2005 Jan; 115(1):128-37. PubMed ID: 15630452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial).
    Stellbrink HJ; van Lunzen J; Westby M; O'Sullivan E; Schneider C; Adam A; Weitner L; Kuhlmann B; Hoffmann C; Fenske S; Aries PS; Degen O; Eggers C; Petersen H; Haag F; Horst HA; Dalhoff K; Möcklinghoff C; Cammack N; Tenner-Racz K; Racz P
    AIDS; 2002 Jul; 16(11):1479-87. PubMed ID: 12131185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy.
    Zhu T; Muthui D; Holte S; Nickle D; Feng F; Brodie S; Hwangbo Y; Mullins JI; Corey L
    J Virol; 2002 Jan; 76(2):707-16. PubMed ID: 11752161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternate NF-κB-Independent Signaling Reactivation of Latent HIV-1 Provirus.
    Acchioni C; Remoli AL; Marsili G; Acchioni M; Nardolillo I; Orsatti R; Farcomeni S; Palermo E; Perrotti E; Barreca ML; Sabatini S; Sandini S; Parolin C; Lin R; Borsetti A; Hiscott J; Sgarbanti M
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31243131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
    Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
    J Virol; 2018 May; 92(9):. PubMed ID: 29444937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation.
    Li P; Kaiser P; Lampiris HW; Kim P; Yukl SA; Havlir DV; Greene WC; Wong JK
    Nat Med; 2016 Jul; 22(7):807-11. PubMed ID: 27294875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short Communication: The Broad-Spectrum Histone Deacetylase Inhibitors Vorinostat and Panobinostat Activate Latent HIV in CD4(+) T Cells In Part Through Phosphorylation of the T-Loop of the CDK9 Subunit of P-TEFb.
    Jamaluddin MS; Hu PW; Jan Y; Siwak EB; Rice AP
    AIDS Res Hum Retroviruses; 2016 Feb; 32(2):169-73. PubMed ID: 26727990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotypic alteration of HAART-persistent HIV-1 reservoirs in vivo.
    Kulkosky J; Sullivan J; Xu Y; Malin-Markham A; Otero M; Calarota S; Zielinski J; Culnan DM; Pomerantz RJ
    Virology; 2003 Sep; 314(2):617-29. PubMed ID: 14554089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART.
    Kulkosky J; Culnan DM; Roman J; Dornadula G; Schnell M; Boyd MR; Pomerantz RJ
    Blood; 2001 Nov; 98(10):3006-15. PubMed ID: 11698284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attacking HIV provirus: therapeutic strategies to disrupt persistent infection.
    Margolis DM; Archin NM
    Infect Disord Drug Targets; 2006 Dec; 6(4):369-76. PubMed ID: 17168802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral blood Dendritic cells are not a major reservoir for HIV type 1 in infected individuals on virally suppressive HAART.
    Otero M; Nunnari G; Leto D; Sullivan J; Wang FX; Frank I; Xu Y; Patel C; Dornadula G; Kulkosky J; Pomerantz RJ
    AIDS Res Hum Retroviruses; 2003 Dec; 19(12):1097-103. PubMed ID: 14709246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy.
    Cillo AR; Sobolewski MD; Bosch RJ; Fyne E; Piatak M; Coffin JM; Mellors JW
    Proc Natl Acad Sci U S A; 2014 May; 111(19):7078-83. PubMed ID: 24706775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GB virus C infection is associated with a reduced rate of reactivation of latent HIV and protection against activation-induced T-cell death.
    Rydze RT; Bhattarai N; Stapleton JT
    Antivir Ther; 2012; 17(7):1271-9. PubMed ID: 22951385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of human immunodeficiency virus-1 latency and its reactivation.
    Verdin E
    Bull Mem Acad R Med Belg; 2008; 163(6):355-64; discussion 364-5. PubMed ID: 19445107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission.
    Lafeuillade A; Poggi C; Chadapaud S; Hittinger G; Chouraqui M; Pisapia M; Delbeke E
    J Acquir Immune Defic Syndr; 2001 Jan; 26(1):44-55. PubMed ID: 11176268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.
    Chege D; Kovacs C; la Porte C; Ostrowski M; Raboud J; Su D; Kandel G; Brunetta J; Kim CJ; Sheth PM; Kaul R; Loutfy MR
    AIDS; 2012 Jan; 26(2):167-74. PubMed ID: 22089379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV Proviral Burden, Genetic Diversity, and Dynamics in Viremic Controllers Who Subsequently Initiated Suppressive Antiretroviral Therapy.
    Omondi FH; Sudderuddin H; Shahid A; Kinloch NN; Jones BR; Miller RL; Tsai O; MacMillan D; Trocha A; Brockman MA; Brumme CJ; Joy JB; Liang R; Walker BD; Brumme ZL
    mBio; 2021 Dec; 12(6):e0249021. PubMed ID: 34781741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy.
    Tsai A; Irrinki A; Kaur J; Cihlar T; Kukolj G; Sloan DD; Murry JP
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28179531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.
    Finzi D; Hermankova M; Pierson T; Carruth LM; Buck C; Chaisson RE; Quinn TC; Chadwick K; Margolick J; Brookmeyer R; Gallant J; Markowitz M; Ho DD; Richman DD; Siliciano RF
    Science; 1997 Nov; 278(5341):1295-300. PubMed ID: 9360927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low Inducibility of Latent Human Immunodeficiency Virus Type 1 Proviruses as a Major Barrier to Cure.
    Siliciano JD; Siliciano RF
    J Infect Dis; 2021 Feb; 223(12 Suppl 2):13-21. PubMed ID: 33586775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.